Affordable Access

Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy.

Authors
  • Prahl, Mary
  • Golan, Yarden
  • Cassidy, Arianna G
  • Matsui, Yusuke
  • Li, Lin
  • Alvarenga, Bonny
  • Chen, Hao
  • Jigmeddagva, Unurzul
  • Lin, Christine Y
  • Gonzalez, Veronica J
  • Chidboy, Megan A
  • Warrier, Lakshmi
  • Buarpung, Sirirak
  • Murtha, Amy P
  • Flaherman, Valerie J
  • Greene, Warner C
  • Wu, Alan HB
  • Lynch, Kara L
  • Rajan, Jayant
  • Gaw, Stephanie L
Publication Date
Jul 01, 2022
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination during pregnancy, and the levels of protection provided to their newborns through placental transfer of antibodies. Here, we evaluate the transplacental transfer of mRNA vaccine products and functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during late pregnancy. We find no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery. However, we find time-dependent efficient transfer of IgG and neutralizing antibodies to the neonate that persists during early infancy. Additionally, using phage immunoprecipitation sequencing, we find a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy. Timing of vaccination during pregnancy is critical to ensure transplacental transfer of protective antibodies during early infancy.

Report this publication

Statistics

Seen <100 times